Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,553 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: IBD Clear all
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 22, 2026, 3:32 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

NCT07463183
View directory record Official record
Conditions
Colitis Ulcerative, Ulcerative Colitis
Interventions
MK-8690, Placebo
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Anaheim, California • Coronado, California • Colorado Springs, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 3:32 AM EDT
Recruiting Not applicable Interventional

Developing a Self-Management Intervention to Improve Health Outcomes for Patients With Inflammatory Bowel Disease

NCT07456566
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions
Digital self-management program, Standard Care
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 22, 2026, 3:32 AM EDT
Terminated Phase 2 Interventional Results available

A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC)

NCT04556383
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
GB004, Placebo
Drug
Lead sponsor
GB004, Inc.
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Encinitas, California • Lancaster, California • Baton Rouge, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 22, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Rimegepant and Placebo for Pain in IBS

NCT06221111
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Rimegepant 75 MG [Nurtec]
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

NCT03555617
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
TD-1473, Itraconazole
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 22, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption

NCT03270085
View directory record Official record
Conditions
Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption
Interventions
Colesevelam, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 22, 2026, 3:32 AM EDT
Completed Not applicable Interventional Results available

Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)

NCT01085643
View directory record Official record
Conditions
Constipation-predominant Irritable Bowel Syndrome
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2011 · Synced Oct 22, 2026, 3:32 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis

NCT00488774
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, Golimumab 1 mg per kg, Golimumab 2 mg per kg, Golimumab 4 mg per kg
Other · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Orange, California • Roseville, California • Littleton, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Oct 22, 2026, 3:32 AM EDT
Not yet recruiting No phase listed Observational

Guselkumab for Overlap Inflammatory Bowel Disease and Spondyloarthritis

NCT07602517
View directory record Official record
Conditions
Spondyloarthritis, Inflammatory Bowel Diseases
Interventions
Guselkumab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 3:32 AM EDT
Completed Not applicable Interventional Results available

Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease.

NCT03241368
View directory record Official record
Conditions
Crohn Disease
Interventions
Capsule Endoscopy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
24
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 22, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis

NCT00269438
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
5 ASA, enemas, suppositories, corticosteroids
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 22, 2026, 3:32 AM EDT
Completed Not applicable Interventional Results available

Stress in Inflammatory Bowel Disease

NCT05202418
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Psychological
Interventions
Biofeedback Enhanced Treatment
Behavioral
Lead sponsor
Emory University
Other
Eligibility
13 Years to 18 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 22, 2026, 3:32 AM EDT
Terminated Phase 2 Interventional

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

NCT06153420
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
CIN-103, Placebo
Drug
Lead sponsor
CinPhloro Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Dothan, Alabama • Huntsville, Alabama • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 22, 2026, 3:32 AM EDT
Completed Phase 4 Interventional Results available

Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis

NCT01124149
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
MMX mesalamine/ mesalazine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
34
States / cities
Birmingham, Alabama • Anaheim, California • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 22, 2026, 3:32 AM EDT
Completed Not applicable Interventional

Effects of an Intermittent Reduced Calorie Diet on Crohn's Disease

NCT04147585
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Diet Modification
Interventions
Intermittent Reduced Calorie Diet (IRCD)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 22, 2026, 3:32 AM EDT
Completed Phase 2 Interventional

Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)

NCT00101985
View directory record Official record
Conditions
Irritable Colon
Interventions
talnetant
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
70
States / cities
Chandler, Arizona • Phoenix, Arizona • North Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 22, 2026, 3:32 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study

NCT05912387
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
Interventions
Rosuvastatin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 22, 2026, 3:32 AM EDT
Terminated Phase 4 Interventional Results available

Pilot Study of Posaconazole in Crohn's Disease

NCT04966585
View directory record Official record
Conditions
Crohn Disease, CARD9 S12N Risk Allele
Interventions
Posaconazole Delayed Release Oral Tablet, Matching Placebo Tablet
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 22, 2026, 3:32 AM EDT
Recruiting Phase 2 Interventional

A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

NCT06764615
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
Zasocitinib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Glen Burnie, Maryland • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 3:32 AM EDT
Recruiting Phase 4 Interventional

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

NCT06581328
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab IV, Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 3:32 AM EDT
Completed Phase 3 Interventional

Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT00552565
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Rezular 15mg, Placebo, Rezular
Drug
Lead sponsor
AGI Therapeutics, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2009 · Synced Oct 22, 2026, 3:32 AM EDT
Recruiting Not applicable Interventional

Diet and Stress Management Combined With Advanced Therapy for Crohn's and Ulcerative Colitis

NCT07168499
View directory record Official record
Conditions
IBD (Inflammatory Bowel Disease)
Interventions
Diet Management, Stress Management
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 22, 2026, 3:32 AM EDT
Completed No phase listed Observational

Pediatric Alliance for International Neurogastrointestinal Functional Research

NCT01099787
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Not listed
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
4 Years to 16 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
6
States / cities
Hartford, Connecticut • Chicago, Illinois • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 22, 2026, 3:32 AM EDT